top of page

Novartis’ phase III MS study successfully meets endpoints

Novartis’ phase III study, evaluating the efficacy and safety of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS), successfully met its primary endpoint of a reduction in the risk of disability progression, compared with placebo.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page